ASH-话题@MedSci

#ASH#

242篇内容 | 2155人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1301218, encodeId=55bc1301218ae, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, objectType=article, longId=122976, objectId=1b1f1229e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1f1229e69f, replyNumber=0, likeNumber=20, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1f1229e69f, moduleTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1f1229e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301217, encodeId=07a5130121e35, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人, objectType=article, longId=122975, objectId=1c8b1229e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8b1229e548, replyNumber=0, likeNumber=28, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8b1229e548, moduleTitle=【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8b1229e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301216, encodeId=5c48130121684, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, objectType=article, longId=122937, objectId=5e1a12293e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e1a12293e5c, replyNumber=0, likeNumber=21, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e1a12293e5c, moduleTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e1a12293e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301215, encodeId=2f001301215ea, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低, objectType=article, longId=122936, objectId=0e7d12293691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e7d12293691, replyNumber=0, likeNumber=21, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e7d12293691, moduleTitle=【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e7d12293691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301214, encodeId=9cec130121434, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响, objectType=article, longId=122935, objectId=add9122935f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add9122935f5, replyNumber=0, likeNumber=25, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add9122935f5, moduleTitle=【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add9122935f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301213, encodeId=5c1a130121399, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, objectType=article, longId=122934, objectId=8533122934c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8533122934c1, replyNumber=0, likeNumber=18, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8533122934c1, moduleTitle=【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8533122934c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301212, encodeId=8e561301212e9, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, objectType=article, longId=122933, objectId=d3461229331a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3461229331a, replyNumber=0, likeNumber=20, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3461229331a, moduleTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3461229331a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301211, encodeId=f07713012114f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】2017美国血液学会年会盛大开幕！, objectType=article, longId=122931, objectId=ab0a1229310e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab0a1229310e, replyNumber=0, likeNumber=25, createdTime=2017-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab0a1229310e, moduleTitle=【2017 ASH】2017美国血液学会年会盛大开幕！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab0a1229310e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301210, encodeId=5298130121013, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】聚焦ASH 2017，走在血液肿瘤科研的**线, objectType=article, longId=122776, objectId=1ba7122e7648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ba7122e7648, replyNumber=0, likeNumber=0, createdTime=2017-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ba7122e7648, moduleTitle=【2017 ASH】聚焦ASH 2017，走在血液肿瘤科研的**线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ba7122e7648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301209, encodeId=1e4e130120969, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, objectType=article, longId=122749, objectId=0a3a122e49ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3a122e49ca, replyNumber=0, likeNumber=19, createdTime=2017-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3a122e49ca, moduleTitle=【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3a122e49ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301208, encodeId=12c41301208b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=24, createdTime=2017-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301207, encodeId=465d130120e27, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】精彩抢先读---淋巴瘤治疗进展看点, objectType=article, longId=122744, objectId=b5c8122e44c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5c8122e44c1, replyNumber=0, likeNumber=26, createdTime=2017-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5c8122e44c1, moduleTitle=【2017 ASH】精彩抢先读---淋巴瘤治疗进展看点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5c8122e44c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301206, encodeId=bffb1301206da, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=JACC：低钠联合DASH饮食能显著改善高血压, objectType=article, longId=122637, objectId=f8da12263e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8da12263e62, replyNumber=0, likeNumber=77, createdTime=2017-12-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8da12263e62, moduleTitle=JACC：低钠联合DASH饮食能显著改善高血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8da12263e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301205, encodeId=bf5a130120516, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】三氧化二砷联合全反式维甲酸在急性早幼粒细胞白血病临床实践中的效果评估, objectType=article, longId=122545, objectId=8dde122545a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dde122545a6, replyNumber=0, likeNumber=68, createdTime=2017-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dde122545a6, moduleTitle=【2017 ASH】三氧化二砷联合全反式维甲酸在急性早幼粒细胞白血病临床实践中的效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dde122545a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301204, encodeId=ef3e13012048e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估, objectType=article, longId=122544, objectId=343112254479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=343112254479, replyNumber=0, likeNumber=54, createdTime=2017-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=343112254479, moduleTitle=【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=343112254479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301203, encodeId=d19e130120322, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, objectType=article, longId=122419, objectId=91ae12241903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91ae12241903, replyNumber=0, likeNumber=22, createdTime=2017-12-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91ae12241903, moduleTitle=【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91ae12241903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301202, encodeId=634b130120218, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, objectType=article, longId=122418, objectId=f1f41224182c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f41224182c, replyNumber=0, likeNumber=28, createdTime=2017-12-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f41224182c, moduleTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f41224182c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301201, encodeId=c10a1301201f8, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH2017前瞻：多发性骨髓瘤（MM）争议问题解答新进展, objectType=article, longId=122150, objectId=389b122150df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=389b122150df, replyNumber=0, likeNumber=62, createdTime=2017-12-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=389b122150df, moduleTitle=ASH2017前瞻：多发性骨髓瘤（MM）争议问题解答新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=389b122150df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301200, encodeId=bdc2130120016, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2017ASH：第59届美国血液学会年会即将召开, objectType=article, longId=122146, objectId=95f012214632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f012214632, replyNumber=0, likeNumber=96, createdTime=2017-12-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f012214632, moduleTitle=2017ASH：第59届美国血液学会年会即将召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95f012214632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301199, encodeId=64c01301199f2, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期, objectType=article, longId=122135, objectId=146112213524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=146112213524, replyNumber=0, likeNumber=60, createdTime=2017-12-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=146112213524, moduleTitle=2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=146112213524)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASH

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】CLARITY研究——伊布替尼联合Venetoclax疗法对复发难治性CLL患者疗效喜人

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】研究证实伊布替尼治疗过程中机会性感染风险极低

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】凋亡抵抗以及NOTCH1基因状态对伊布替尼治疗预后的影响

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼+奥法木单抗+Venetoclax联合治疗用于未经治疗的CLL患者

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】2017美国血液学会年会盛大开幕！

2017-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】聚焦ASH 2017，走在血液肿瘤科研的**线

2017-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼联合FCR一线治疗中青年慢性淋巴细胞白血病——多中心II临床研究结果

2017-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2017-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】精彩抢先读---淋巴瘤治疗进展看点

2017-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

JACC：低钠联合DASH饮食能显著改善高血压

2017-12-09

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】三氧化二砷联合全反式维甲酸在急性早幼粒细胞白血病临床实践中的效果评估

2017-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】Venetoclax在复发或难治性del17p突变慢性淋巴细胞白血病临床实践中的效果评估

2017-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】慢性淋巴细胞白血病临床实践中伊布替尼的疗效考察：治疗响应、毒性、结果和后续治疗

2017-12-07

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病

2017-12-07

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH2017前瞻：多发性骨髓瘤（MM）争议问题解答新进展

2017-12-04

kksonne (审核中...)

前往app查看评论内容

#ASH#

2017ASH：第59届美国血液学会年会即将召开

2017-12-04

kksonne (审核中...)

前往app查看评论内容

#ASH#

2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期

2017-12-04

科室
- - 订阅+
  - 更多科室
工具
服务